JP2018505901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505901A5 JP2018505901A5 JP2017543816A JP2017543816A JP2018505901A5 JP 2018505901 A5 JP2018505901 A5 JP 2018505901A5 JP 2017543816 A JP2017543816 A JP 2017543816A JP 2017543816 A JP2017543816 A JP 2017543816A JP 2018505901 A5 JP2018505901 A5 JP 2018505901A5
- Authority
- JP
- Japan
- Prior art keywords
- daily dose
- day
- schizophrenia
- iloperidone
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims description 20
- 201000000980 schizophrenia Diseases 0.000 claims description 17
- 229960003162 iloperidone Drugs 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 2
- 238000011418 maintenance treatment Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 description 17
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117173P | 2015-02-17 | 2015-02-17 | |
| US62/117,173 | 2015-02-17 | ||
| US201562172436P | 2015-06-08 | 2015-06-08 | |
| US62/172,436 | 2015-06-08 | ||
| PCT/US2016/018316 WO2016134049A1 (en) | 2015-02-17 | 2016-02-17 | Iloperidone for the treatment of schizophrenia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505901A JP2018505901A (ja) | 2018-03-01 |
| JP2018505901A5 true JP2018505901A5 (enExample) | 2019-03-28 |
| JP6885649B2 JP6885649B2 (ja) | 2021-06-16 |
Family
ID=55532275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543816A Active JP6885649B2 (ja) | 2015-02-17 | 2016-02-17 | 統合失調症の治療のためのイロペリドン |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10441580B2 (enExample) |
| EP (1) | EP3258935B1 (enExample) |
| JP (1) | JP6885649B2 (enExample) |
| KR (1) | KR102870956B1 (enExample) |
| CN (2) | CN116211857A (enExample) |
| BR (1) | BR112017017608A2 (enExample) |
| CA (1) | CA2976383C (enExample) |
| ES (1) | ES2870498T3 (enExample) |
| WO (1) | WO2016134049A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
| JP2026504721A (ja) * | 2022-12-19 | 2026-02-09 | バンダ・ファーマシューティカルズ・インコーポレイテッド | 双極ｉ型障害及び統合失調症の治療のためのイロペリドンの投与レジメン |
| WO2024249952A1 (en) | 2023-06-02 | 2024-12-05 | Vanda Pharmaceuticals Inc. | Method of treatment with iloperidone |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2305656T3 (da) | 2001-08-31 | 2013-02-11 | Novartis Ag | Optiske isomerer of en iloperidonmetabolit |
| ES2358416T3 (es) | 2001-10-30 | 2011-05-10 | Novartis Ag | Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella. |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| CA3113166A1 (en) * | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| WO2009036056A1 (en) | 2007-09-10 | 2009-03-19 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on snp genotype |
| KR20100099292A (ko) * | 2007-12-19 | 2010-09-10 | 얀센 파마슈티카 엔.브이. | 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법 |
| CA2760474C (en) * | 2009-05-15 | 2020-08-18 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on drd2 or ankk1 snp genotype |
| EP2785347A1 (en) * | 2011-12-02 | 2014-10-08 | Dainippon Sumitomo Pharma Co., Ltd. | Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder |
| IN2014DN08495A (enExample) | 2012-03-14 | 2015-05-08 | Vanda Pharmaceuticals Inc | |
| IL275725B (en) * | 2012-08-21 | 2022-08-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
-
2016
- 2016-02-17 ES ES16710038T patent/ES2870498T3/es active Active
- 2016-02-17 CN CN202310398029.9A patent/CN116211857A/zh active Pending
- 2016-02-17 EP EP16710038.7A patent/EP3258935B1/en active Active
- 2016-02-17 KR KR1020177026225A patent/KR102870956B1/ko active Active
- 2016-02-17 US US15/549,820 patent/US10441580B2/en active Active
- 2016-02-17 WO PCT/US2016/018316 patent/WO2016134049A1/en not_active Ceased
- 2016-02-17 CA CA2976383A patent/CA2976383C/en active Active
- 2016-02-17 CN CN201680010479.4A patent/CN107249586A/zh active Pending
- 2016-02-17 BR BR112017017608-4A patent/BR112017017608A2/en not_active Application Discontinuation
- 2016-02-17 JP JP2017543816A patent/JP6885649B2/ja active Active
-
2019
- 2019-09-06 US US16/562,548 patent/US10987346B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012193216A5 (enExample) | ||
| JP2020023574A5 (ja) | 近視予防、治療又は抑制用点眼剤、及び、小胞体ストレス抑制用点眼剤 | |
| JP2015512406A5 (enExample) | ||
| JP2017531033A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| JP2010523587A5 (enExample) | ||
| JP2015515985A5 (enExample) | ||
| JP2019517542A5 (enExample) | ||
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2018529742A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| JP2017503014A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2014520856A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2017105859A5 (enExample) | ||
| JP2018529666A5 (enExample) | ||
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| JP2018521007A5 (enExample) | ||
| JP2014507475A5 (enExample) | ||
| JP2020533296A5 (enExample) | ||
| JP2018505901A5 (enExample) | ||
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| JP2019507786A5 (enExample) |